Recent Updates
Recently added Catalysts
CSCI

STATEMENT OF EXECUTIVE COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2021 Remuneration of Directors The compensation paid to members of the Aeterna Zentaris Inc. (the " Corporation " or " Aeterna Zentaris ") Board of Dire

Key Takeaway: OF EXECUTIVE COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2021 compensation paid to members of the Aeterna Zentaris Inc. (the "Corporation" or "Aeterna Zentaris") Board of Directors (the "Board") who are not employees ("Outside Directors") is designed to (i) attract and retain

Full Press Release Details

OF EXECUTIVE COMPENSATION FOR THE YEAR ENDED DECEMBER 31, 2021
compensation paid to members of the Aeterna Zentaris Inc. (the "Corporation" or "Aeterna Zentaris")
Board of Directors (the "Board") who are not employees ("Outside Directors") is designed to (i)
attract and retain the most qualified people to serve on the Board and its committees, (ii) align the interests of the Outside Directors
with those of our shareholders, and (iii) provide appropriate compensation for the risks and responsibilities related to being an effective
Outside Director. This compensation is recommended to the Board by the Nominating, Governance and Compensation Committee (the "NGCC").
The NGCC is currently composed of three Outside Directors, each of whom is independent, namely Ms. Carolyn Egbert (Chair), Mr. Peter
G. Edwards and Mr. Gilles Gagnon.
Board has adopted a formal mandate for the NGCC which is available on our website at www.zentaris.com. The mandate of the NGCC
provides that it is responsible for, among other matters, assisting the Board in developing our approach to corporate governance issues,
proposing new Board nominees, overseeing the assessment of the effectiveness of the Board and its committees, their respective chairs
and individual directors, making recommendations to the Board with respect to directors' compensation and generally serving in
a leadership role for our corporate governance practices.
dollar amounts herein are in United States (US) dollars, unless indicated as Canadian dollars (C) or European Dollars ( ).
of Outside Directors
Outside Directors are paid an annual retainer, the amount of which depends on the position held on the Board. Our Outside Directors will
not be paid fees for their attendance of meetings, unless some circumstance dictates that an unusual and burdensome number of meetings
must be held. If such circumstance occurs, the Board may institute meeting payments. The annual retainers are paid in quarterly instalments
on or about the last day of each calendar quarter. All payments are calculated in U.S. dollars. The amount of each payment is converted
to the Outside Director's home currency based on the exchange rate prevailing on the date of payment, as determined by our finance
department. Each Outside Director is paid the equivalent value of the payment in his or her home currency, net of any withholdings or
deductions required by applicable law.
April 2020, the NGCC retained Bowers Consulting LLC ("Bowers"), an independent consulting firm, to ensure that the
compensation of the Directors was aligned with Shareholders' expectations and to reflect the cash position of the Corporation at
that time. The mandate given to Bowers was to provide an objective recommendation regarding the compensation of Directors for the 2020
financial year. Based on the advice received by the NGCC from Bowers, the NGCC recommended, and the Board approved, a reduction of the
annual retainer to be paid to the Chair of the Board and each member of the Board, as well as to the Chair of the NGCC, as set out in
the table below. These reductions were effective immediately after the Corporation's Annual General Meeting held on May 15, 2020,
and were prorated through the balance of the financial year. The Corporation paid fees to Bowers in the amount of $ 1,800 for the 2019,
$2,400 for the 2020 and $3,300 for 2021 financial years.
amounts of the annual retainers are set forth in the following table. The amounts shown below are on an annualized basis. See the table
in below under the caption "Total Compensation of Outside Directors" for details on the actual amounts paid to each Outside
Director during the 2021 financial year.
Type of Compensation Annual Retainer ($)
Chair of the Board Retainer 60,000
Board Member Retainer 30,000
Audit Committee Chair Retainer 20,000
Audit Committee Member Retainer 5,000
NGCC Chair Retainer 10,000
NGCC Member Retainer 3,000
Directors are reimbursed for travel and other out-of-pocket expenses incurred in attending Board or committee meetings. Retainers are
prorated when an Outside Director joins the Board during a financial year.
Option-Based Awards and Share-Based Awards
following table shows all awards outstanding to each Outside Director as at December 31, 2021:
Option-based Awards Share-based Awards
Name Issuance Date (mm-dd-yyyy) Number of Securities Underlying Unexercised Options (#) Option Exercise Price ($) Option Expiration Date (mm-dd-yyyy) Value of Unexercised in-the-money Options (1) ($) Issuance Date (mm-dd-yyyy) Number of Shares or Units of Shares that have not vested (#) Market or payout value of share-based awards that have not vested (2) ($) Market or payout value of vested share-based awards not paid out or distributed ($)
Edwards, Peter - - - - - 05/15/2020 30,000 - 10,800
- - - - - 05/05/2021 70,000 - 25,200
Egbert, Carolyn 05-10-2016 10,000 3.48 05-09-2023 - - - - -
12-06-2016 7,850 3.45 12-06-2023 - - - - -
08-15-2017 60,000 2.05 08-15-2024 - - - - -
- - - - - 05/08/2018 23,000 - 8,280
- - - - - 05/22/2019 30,000 - 10,800
05/15/2020 30,000 - 10,800
- - - - - 05/15/2021 70,000 - 25,200
Gagnon, Gilles - - - - - 05/15/2020 30,000 - 10,800
- - - - - 05/19/2021 70,000 - 25,200
Turpin, Dennis (3) - - - - - 05/19/2021 70,000 - 25,200
"Value of unexercised in-the-money options" at financial year-end is calculated based on the difference between the closing
prices of the Corporation's common shares ("Common Shares") on the Nasdaq Capital Market ("Nasdaq")
on the last trading day of the fiscal year (December 31, 2021) of $0.36 and the exercise price of the options, multiplied by the number
of unexercised options.
The Corporation used the closing price of its Common Shares on the Nasdaq as at the last trading day of the fiscal year (December 31,
Mr. Dennis Turpin joined the Board on May 5, 2021.
Compensation of Outside Directors
table below summarizes the total compensation paid to our Outside Directors during the financial year ended December 31, 2021 (all amounts
are in U.S. dollars). Our Outside Directors are generally paid in their home currency. Mr. Desbiens, Mr. Gagnon and Mr. Turpin were paid
in Canadian dollars. Ms. Egbert and Mr. Edwards were paid in U.S. dollars.
Name Fees earned (1) ($) Share-based Awards (2) ($) Option-based Awards ($) Non-Equity Incentive Plan Compensation ($) Pension Value ($) All Other Compensation ($) Total ($)
Desbiens, Pierre-Yves (3) 25,000 - - - - - 25,000
Edwards, Peter 38,000 60,753 - - - - 98,753
Egbert, Carolyn 70,000 60,753 - - - - 130,753
Gagnon, Gilles 38,000 60,753 - - - - 98,753
Turpin, Dennis (4) 32,778 60,753 - - - - 93,531
In respect of our financial year ended December 31, 2021, we paid an aggregate amount of $203,778 to all of our Outside Directors for
services rendered in their capacity as directors, excluding reimbursement of out-of-pocket expenses and the value of share-based and
option-based awards granted in 2021.
Amounts shown represent the value of the Deferred Share Units ("DSUs") on the grant date ($0.89). The value of one DSU on
the grant date is the closing price of one Common Share on the Nasdaq on the last trading day preceding the date of grant.
Mr. Pierre-Yves Desbiens served on the Board until May 5, 2021.
Mr. Dennis Turpin joined the Board on May 5, 2021.
of Executive Officers
following is disclosure of information related to the compensation that we paid to our Named Executive Officers during 2021. For the
2021 year, our Named Executive Officers were as follows:
Dr. Klaus Paulini, who, since October 4, 2019, has served President and Chief Executive Officer, as well as Managing Director of Aeterna Zentaris GmbH (" AEZS Germany "), since July 2019;
Ms. Leslie Auld, who, since September 24, 2018, has served as Senior Vice President, Chief Financial Officer as an independent contractor; and
Dr. Matthias Gerlach, who serves as the Senior Vice President Manufacturing and Supply Chain; Dr. Eckhard Guenther, who serves as Senior Vice President Business Development & Alliance Management and Managing Director AEZS Germany; and Dr. Nicola Ammer, who serves as Chief Medical Officer and Senior Vice President Clinical Development, who were our three most highly compensated executive officers (other than our Chief Executive Officer and our Chief Financial Officer) employed at the end of 2021.
compensation of executive officers of the Corporation and its subsidiaries is recommended to the Board by the NGCC. The NGCC is responsible
for, among other matters, (i) assisting the Board in developing our approach to corporate governance issues, (ii) proposing new Board
nominees, (iii) overseeing the assessment of the effectiveness of the Board and its committees, their respective chairs and individual
directors and (iv) making recommendations to the Board with respect to board member nominees and directors' compensation, as well
as serving in a leadership role for our corporate governance practices. It is also responsible for taking all reasonable actions to ensure
that appropriate human resources policies, procedures and systems, e.g., recruitment and retention policies, competency and performance
metrics and measurements, training and development programs, and market-based, competitive compensation and benefits structures, are
in place so that we can attract, motivate and retain the quality of personnel required to achieve our business objectives. The NGCC also
assists the Board in discharging its responsibilities relating to the recruitment, retention, development, assessment, compensation and
succession planning for our executive and senior management members.
the NGCC recommends the appointment of senior officers, including the terms and conditions of their appointment and termination, and
reviews the evaluation of the performance of our senior officers, including recommending their compensation and overseeing risk identification
and management in relation to executive compensation policies and practices. The Board, which includes the members of the NGCC, reviews
the Chief Executive Officer's corporate strategy, goals and performance objectives and evaluates and measures his or her performance
and compensation against the achievement of such goals and objectives.
NGCC recognizes that the industry, regulatory and competitive environment in which we operate requires a balanced level of risk-taking
to promote and achieve the performance expectations of executives of a specialty biopharmaceutical company. The NGCC is of the view that
our executive compensation program should not encourage senior executives to take inappropriate or unreasonable risk. In this regard,
the NGCC recommends the implementation of compensation methods that appropriately connect a portion of senior executive compensation
with our short-term and longer-term performance, as well as that of each individual executive officer and that take into account the
advantages and risks associated with such compensation methods. The NGCC is also responsible for establishing compensation policies that
are intended to reward the creation of shareholder value while reflecting a balance between our short-term and longer-term performance
and that of each executive officer.
NGCC is currently composed of Ms. Carolyn Egbert (Chair), Mr. Peter G. Edwards and Mr. Gilles Gagnon, each of whom is independent. The
Board believes that the members of the NGCC collectively have the knowledge, experience and background required to fulfill its mandate:
Carolyn Egbert has served as a director on our Board since August 2012 and as Chair of our Board since May 2016. After enjoying the
private practice of law as a defence litigator in Michigan and Washington, D.C., she joined Solvay America, Inc. ("Solvay")
(a chemical and pharmaceutical company) in Houston, Texas. Over the course of a twenty-year career with Solvay, she held the positions
of Vice President, Human Resources, President of Solvay Management Services, Global Head of Human Resources and Senior Executive Vice
President of Global Ethics and Compliance. During her tenure with Solvay, she served as a director on the board of directors of seven
subsidiary companies and as Chair of one subsidiary board. After retiring in 2010, she established Creative Solutions for executives,
a consulting business providing expertise in corporate governance, ethics and compliance, organizational development, executive compensation
and strategic human resources. She holds a Bachelor of Sciences degree in Biological Sciences from George Washington University, Washington
D.C., and a Juris Doctor degree from Seattle University, Seattle, Washington. She also was a Ph.D. candidate in Pharmacology at both
Georgetown University Medical School at Washington, D.C. and Northwestern University Medical School at Chicago, Illinois. She remains
an active member of both the Michigan State Bar and the District of Columbia Bar, Washington, D.C.
G. Edwards joined the Board on May 15, 2020 and served as the Executive Vice President and General Counsel of Celanese Corporation
from January 2017 to January 2019. Mr. Edwards previously was Executive Vice President and General Counsel of Baxalta Incorporated, the
biopharmaceutical spin-off from Baxter, from June 2015 until its merger with Shire plc in July 2016. Before that, he was Senior Vice
Last updated: May 17, 2022